Biorithm, a Singapore-based global women's medical technology company involved in developing solutions for personalised connected maternity care, including Femom, a comprehensive remote obstetric monitoring system, announced on Monday that it has named Jenny Hoffmann, PhD as its new CEO.
Dr Hoffmann has served for 13 years in executive positions at WL Gore & Associates, including business leadership for various medical devices. She holds a Bachelor of Science degree in Engineering and Applied Science from the University of Virginia. She has completed her PhD in Bioengineering from Rice University.
Amrish Nair, founder, CTO and chairman of the Biorithm board, said, 'Dr Hoffmann is a visionary executive with a history of development and commercialisation of medical devices that improve patients' lives. On behalf of the Biorithm board, I welcome Dr Hoffmann and look forward to her leadership in bringing Biorithm's vision to life for clinicians and patients around the world.'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business
Insmed receives highest ranking in Science's 2024 Top Employers Survey
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions